Mifamurtide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Mifamurtide: From Osteosarcoma (Unconfirmed) to Filariasis
One-Sentence Summary
Mifamurtide is a liposomal formulation of muramyl tripeptide phosphatidylethanolamine (MTP-PE), though its original indication is not confirmed in this evidence pack. The TxGNN model predicts it may be effective for Filariasis, but currently no clinical trials and no supporting literature exist for this specific pairing — the prediction rests solely on an indirect, low-confidence mechanistic inference.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no license data or original indication text in this evidence pack) |
| Predicted New Indication | Filariasis |
| TxGNN Prediction Score | 93.06% |
| Evidence Level | L5 |
| EU Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on the repurposing rationale provided, Mifamurtide is a liposomal MTP-PE (muramyl tripeptide phosphatidylethanolamine) that activates NOD2 signaling in monocytes/macrophages, inducing pro-inflammatory cytokines (TNF-α, IL-1, IL-6). This is a general macrophage-activating immunostimulant mechanism rather than a disease-specific one.
The proposed link to filariasis is that enhanced macrophage activation might theoretically improve host immune clearance of filarial parasites. However, this is explicitly flagged in the rationale as a weak, indirect inference — there is no direct literature or trial evidence connecting Mifamurtide to filariasis, and the established first-line treatment for filariasis is antiparasitic chemotherapy, not immune stimulation. The biological plausibility here is low.
Notably, several other top-10 predictions for this drug (autoimmune oophoritis, type 1 diabetes mellitus, diabetic nephropathy) show mechanistically contradictory rationale — Mifamurtide’s pro-inflammatory action could plausibly worsen these autoimmune/inflammatory conditions rather than treat them. This pattern across the candidate set suggests the model is picking up on the drug’s general immunostimulant signature rather than disease-specific therapeutic relevance, which should temper confidence in the top-ranked prediction as well.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
EU Market Information
No EU marketing authorizations are currently on record for this drug in the evidence pack (market status: not marketed, 0 licenses).
Safety Considerations
Please refer to the SmPC for safety information.
Note: Mechanism of action, key warnings, and contraindications are flagged as a Blocking data gap (DG001) in this evidence pack — TFDA/EMA label data has not yet been retrieved, which prevents a preliminary safety (S1) assessment.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (filariasis) has no clinical trial or literature support and rests on a single, explicitly weak mechanistic inference (L5, S0). Several lower-ranked candidates for this same drug show mechanistically contradictory rationale, suggesting the model’s overall signal for Mifamurtide reflects generic immunostimulant activity rather than indication-specific therapeutic relevance. Combined with the absence of EU marketing status and a Blocking-severity safety data gap, there is insufficient basis to advance this candidate.
To proceed, the following is needed:
- Confirmed original indication and mechanism of action (DrugBank API query, per DG002)
- TFDA/EMA label warnings, contraindications, and DDI data (per DG001, Blocking — required before any S1 safety evaluation)
- Direct clinical or preclinical evidence specifically linking Mifamurtide to filariasis (or reconsideration of lower-scoring but mechanistically coherent candidates)
- Clarification of “not marketed” status in this evidence pack, given inconsistency with the drug’s known regulatory history
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.